CPMD · Cannapharmarx, Inc.
$0.00
+0.00 (+0.00%)
At close · Aug 31
View the 10-Q filed May 20, 2026
Going-concern doubt
— flagged Aug 18, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Substantial doubt exists as to our ability to continue as a going concern based on the fact that we do not have adequate working capital to finance our day-to-day operations.”View the 10-Q filed Aug 18, 2026
Customer concentration
— key customers 100% of revenue
Key customers — 100% of revenue (three months ended March 31, 2026)
“During the three months ended March 31, 2026, the Company recognized all of its revenue of $627,462 (2025 - $nil) from related parties being D.N.S. CANTEK 2019 LTD ("Cantek"), an Israeli limited corporation owned 100% by Koze, and for which Mr. Tal serves as a financial advisor.”
Market Cap
$1.56M
Shares
708.69M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Dominic Colvin | CEO | $64,038 |
| Gary Herick | CFO, Secretary | $56,500 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Gary Herick | CFO, Secretary | $199,300 |
| Dominic Colvin | CEO | $27,500 |
| Jim Samuelson | — | $27,500 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Rick Orman | member of the Board | Resigned | 2026-01-13 |
| Elliot Zemel | Board | Appointed | 2025-03-31 |
| Constantine Nkafu | Board | Appointed | 2025-03-31 |
| Constantine Nkafu | interim CEO | Appointed | 2025-03-31 |
| Dean Medwid | Chief Executive Officer | Resigned | 2024-09-17 |
| Oliver Foeste | Chief Financial Officer | Appointed | 2023-10-13 |
| Anthony Michael Panek | member of the Board | Appointed | 2023-08-28 |
| Adam Mindle | member of the Board | Appointed | 2023-08-28 |
| Mark Branson | member of the Board | Resigned | 2023-08-28 |
| Dean Medwid | Chief Executive Officer | Appointed | 2023-06-23 |
| Dominic Colvin | Chief Executive Officer ("CEO") | Resigned | 2023-06-23 |